Core Viewpoint - The National Medical Products Administration emphasizes the importance of formulating the "14th Five-Year" drug planning to enhance drug regulation capabilities and promote high-quality development of the pharmaceutical industry, aiming to transition China from a major pharmaceutical country to a strong pharmaceutical nation [1] Group 1: Drug Regulation Development - The meeting highlighted the need to develop an overall strategy for drug regulation during the "14th Five-Year" period [1] - It aims to address deep-seated contradictions and issues in drug regulation, enhancing governance capabilities [1] - The focus is on creating a comprehensive drug safety responsibility system and a full-chain regulatory mechanism [1] Group 2: Reform and Innovation - There is a call for comprehensive deepening of drug review and approval system reforms [1] - The meeting encourages the innovation and development of traditional Chinese medicine and high-end medical devices [1] - It also emphasizes the need to reform the review and approval mechanisms for cosmetics to promote high-quality development [1] Group 3: Regulatory Capacity Building - The meeting stresses the importance of improving the regulatory standards and legal framework [1] - It highlights the need for strengthening technical support capabilities and leading with information technology [1] - The goal is to build a high-quality team of drug regulatory professionals to enhance overall regulatory capabilities [1]

Core Viewpoint - The document emphasizes the exploration of feasible pathways to utilize international new drug clinical real-world data for the registration and licensing of imported pharmaceuticals in China [1] Group 1: Regulatory Reforms - The document outlines the need to deepen the reform of the drug and medical device review and approval system [1] - It highlights the enhancement of drug supervision and inspection capabilities at ports [1] - The document mentions the improvement of management systems for urgently needed imported drugs and medical devices [1] Group 2: Digital Governance - The document calls for the advancement of digital government reforms to elevate the level of intelligent and specialized social governance [1]